miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen

- January 11th, 2019

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma (CTCL) and in adult T-cell leukemia/lymphoma (ATLL). As quoted in the press release: The … Continued

miRagen Therapeutics (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability and efficacy of cobomarsen, an inhibitor of microRNA-155, in cutaneous T-cell lymphoma (CTCL) and in adult T-cell leukemia/lymphoma (ATLL).

As quoted in the press release:

The Company will also discuss initial clinical experience in treating diffuse large B-cell lymphoma (DLBCL) patients with cobomarsen. The data will be presented at the 11th Annual T-Cell Lymphoma Forum, which is being held in La Jolla, CA, from January 10th-12th.

“The ATLL clinical data shows that cobomarsen provided sustained disease stabilization in five patients for up to 13 months after completing chemotherapy or experimental treatment and an improvement in the levels of normal circulating blood cells.  In addition, patients did not report any significant side effects attributed to cobomarsen. We believe these data are particularly encouraging, as the patients in this study had previously failed on other therapies and the median survival for patients with acute disease typically ranges from four to ten months after diagnosis,” stated Paul Rubin M.D. Executive Vice President, R&D, at miRagen. “We are encouraged by our early experience in the ABC subtype of DLBCL, as we have observed an improvement in a patient that had long-standing disease and had previously been on multiple chemotherapeutic regimens.”

Click here to read the full press release.

Find out what experts are saying about the future of cannabis


Read our new report today

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *